TABLE 3.
Change in anti‐acetylcholine receptor antibody concentration in patients with/without thymoma and/or thymectomy (multivariable logistic regression)
| Obs | Event n (%) | n | OR | 95% CI | p value | |
|---|---|---|---|---|---|---|
| No thymectomy | ||||||
| Model 1 a | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 27 | 22 (81) | 1.89 | 0.48–7.48 | 0.367 | |
| Decrease 0%–50% | 59 | 43 (73) | Reference | Reference | Reference | |
| Increase | 24 | 5 (21) | 0.05 | 0.01–0.27 | 0.001 | |
| Continuous (per 10% decrease) | 110 | 70 (64) | 41 | 1.45 | 1.17–1.80 | 0.001 |
| Model 2 b | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 27 | 22 (81) | 1.68 | 0.40–6.99 | 0.479 | |
| Decrease 0%–50% | 59 | 43 (73) | Reference | Reference | Reference | |
| Increase | 24 | 5 (21) | 0.05 | 0.09–0.26 | <0.001 | |
| Continuous (per 10% decrease) | 110 | 70 (64) | 41 | 1.45 | 1.17–1.80 | 0.001 |
| Thymectomy | ||||||
| Model 1 a | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 26 | 24 (92) | 10.78 | 2.38–48.73 | 0.002 | |
| Decrease 0%–50% | 99 | 53 (54) | Reference | Reference | Reference | |
| Increase | 60 | 24 (40) | 0.58 | 0.30–1.13 | 0.107 | |
| Continuous (per 10% decrease) | 185 | 101 (55) | 49 | 1.15 | 1.05–1.25 | 0.002 |
| Model 2 b | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 26 | 24 (92) | 10.49 | 2.32–47.38 | 0.002 | |
| Decrease 0%–50% | 99 | 53 (54) | Reference | Reference | Reference | |
| Increase | 60 | 24 (40) | 0.57 | 0.29–1.12 | 0.101 | |
| Continuous (per 10% decrease) | 185 | 101 (55) | 49 | 1.14 | 1.05–1.25 | 0.003 |
| p‐interaction c (thymectomy: yes vs. no) | 0.067 | |||||
| No thymoma | ||||||
| Model 1 a | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 39 | 33 (85) | 3.56 | 1.31–9.65 | 0.013 | |
| Decrease 0%–50% | 137 | 84 (61) | Reference | Reference | Reference | |
| Increase | 69 | 24 (35) | 0.30 | 0.16–0.58 | <0.001 | |
| Continuous (per 10% decrease) | 245 | 141 (58) | 73 | 1.19 | 1.10–1.30 | <0.001 |
| Model 2 b | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 39 | 33 (85) | 3.21 | 1.17–8.85 | 0.024 | |
| Decrease 0%–50% | 137 | 84 (61) | Reference | Reference | Reference | |
| Increase | 69 | 24 (35) | 0.31 | 0.16–0.60 | 0.001 | |
| Continuous (per 10% decrease) | 245 | 141 (58) | 73 | 1.18 | 1.09–1.28 | <0.001 |
| Thymoma | ||||||
| Model 1 a | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 14 | 13 (93) | 9.97 | 1.09–91.46 | 0.042 | |
| Decrease 0%–50% | 21 | 12 (57) | Reference | Reference | Reference | |
| Increase | 15 | 5 (33) | 0.38 | 0.10–1.51 | 0.170 | |
| Continuous (per 10% decrease) | 50 | 30 (60) | 17 | 1.36 | 1.10–1.69 | 0.005 |
| Model 2 b | ||||||
| Change in anti‐AChR‐ab concentration | ||||||
| Decrease ≥50% | 14 | 13 (93) | 10.33 | 1.11–96.18 | 0.040 | |
| Decrease 0%–50% | 21 | 12 (57) | Reference | Reference | Reference | |
| Increase | 15 | 5 (33) | 0.37 | 0.09–1.51 | 0.166 | |
| Continuous (per 10% decrease) | 50 | 30 (60) | 17 | 1.37 | 1.10–1.70 | 0.005 |
| p‐interaction c (thymoma: yes vs. no) | 0.147 | |||||
Event was defined as improvement in MGFA score.
Abbreviations: AChR‐ab, anti‐acetylcholine receptor antibody; n = number of individuals; Obs = number of observations.
a
Additionally adjusted for time since baseline measurement (months; continuous).
b
Model 1 additionally adjusted for age (years), and sex (male/female).
c
p‐interaction calculated based on continuous outcome (per 10% decrease), Model 2.